➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Moodys
Colorcon
McKinsey
Boehringer Ingelheim

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

DANOCRINE Drug Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Danocrine, and what generic alternatives are available?

Danocrine is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in DANOCRINE is danazol. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the danazol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Danocrine

A generic version of DANOCRINE was approved as danazol by BARR on August 9th, 1996.

  Get Started Free

Drug patent expirations by year for DANOCRINE
Recent Clinical Trials for DANOCRINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Peking University People's HospitalPhase 2
Sierra Oncology, Inc.Phase 3
Peking University People's HospitalPhase 1/Phase 2

See all DANOCRINE clinical trials

US Patents and Regulatory Information for DANOCRINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us DANOCRINE danazol CAPSULE;ORAL 017557-003 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free   Get Started Free
Sanofi Aventis Us DANOCRINE danazol CAPSULE;ORAL 017557-004 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free   Get Started Free
Sanofi Aventis Us DANOCRINE danazol CAPSULE;ORAL 017557-002 Approved Prior to Jan 1, 1982 DISCN No No   Get Started Free   Get Started Free   Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Colorcon
Dow
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.